文献速递胸部肿瘤放疗放疗物理与技术

质子放疗对比光子放疗治疗非小细胞肺癌患者的成本效益:探索基于模型的方法

Cost-effectiveness of proton radiotherapy versus photon radiotherapy for non-small cell lung cancer patients: Exploring the model-based approach.
PubMed 文献 · Radiother Oncol · 2022-11-12

本研究构建决策分析模型,比较III期非小细胞肺癌三种放疗策略的成本与质量调整生命年:全部光子放疗、全部质子放疗、基于正常组织并发症概率模型选择患者行质子放疗。全部光子放疗成本效益最优;全部质子放疗获得QALY最多但费用最高;仅在每分次15分钟假设下,个体化质子放疗成本效益最优(ICER 76,299欧元)。

要点

  • 全部光子放疗为成本效益最优策略,全部质子放疗QALY最多但费用最高。
  • 阈值高于每QALY 163,467欧元时,个体化质子放疗具有成本效益。
  • 假设质子与光子每分次均为15分钟时,个体化质子放疗成本效益最优(ICER 76,299欧元)。

核心结论

  • 目前质子放疗对所有III期非小细胞肺癌患者、或按荷兰适应证方案所用NTCP模型选择患者均不具成本效益。
  • 随着临床经验提升及质子放疗人员与治疗成本下降,个体化质子放疗结合最优患者选择可能成为具成本效益的策略。

研究设计与样本

  • 构建决策分析模型,估算并比较III期非小细胞肺癌三种放疗策略的成本与QALY。
  • 三种策略为全部患者光子放疗、全部患者质子放疗、选择患者质子放疗。
  • 纳入放射性呼吸困难、吞咽困难和心脏毒性三类毒性,分别计入2级和≥3级毒性的成本与QALY。

主要发现

  • 全部质子放疗获得QALY最多但费用最高。
  • 全部光子放疗效果最差且费用最低,为成本效益最优策略。
  • 阈值高于每QALY 163,467欧元时,个体化质子放疗具成本效益。
  • 假设质子与光子每分次均为15分钟时,个体化质子放疗成本效益最优(ICER 76,299欧元)。

关键数值与推荐

  • ICER计算并与80,000欧元阈值比较。
  • 阈值高于每QALY 163,467欧元时,个体化质子放疗具成本效益。
  • 质子与光子每分次均为15分钟假设下,个体化质子放疗ICER为76,299欧元。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Proton radiotherapy (PT) is a promising but more expensive strategy than photon radiotherapy (XRT) for the treatment of non-small cell lung cancer (NSCLC). PT is probably not cost-effective for all patients. Therefore, patients can be selected using normal tissue complication probability (NTCP) models with predefined criteria. This study aimed to explore the cost-effectiveness of three treatment strategies for patients with stage III NSCLC: 1. photon radiotherapy for all patients (XRTAll); 2. PT for all patients (PTAll); 3. PT for selected patients (PTIndividualized). METHODS: A decision-analytical model was constructed to estimate and compare costs and QALYs of all strategies. Three radiation-related toxicities were included: dyspnea, dysphagia and cardiotoxicity. Costs and QALY's were incorporated for grade 2 and ≥ 3 toxicities separately. Incremental Cost-Effectiven Ratios (ICERs) were calculated and compared to a threshold value of €80,000. Additionally, scenario, sensitivity and value of information analyses were performed. RESULTS: PTAll yielded most QALYs, but was also most expensive. XRTAll was the least effective and least expensive strategy, and the most cost-effective strategy. For thresholds higher than €163,467 per QALY gained, PTIndividualized was cost-effective. When assuming equal minutes per fraction (15 minutes) for PT and XRT, PTIndividualized was considered the most cost-effective strategy (ICER: €76,299). CONCLUSION: Currently, PT is not cost-effective for all patients, nor for patient selected on the current NTCP models used in the Dutch indication protocol. However, with improved clinical experience, personnel and treatment costs of PT can decrease over time, which potentially leads to PTIndividualized, with optimal patient selection, will becoming a cost-effective strategy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Aldenhoven L, Ramaekers B, Degens J, et al. Cost-effectiveness of proton radiotherapy versus photon radiotherapy for non-small cell lung cancer patients: Exploring the model-based approach. Radiother Oncol. 2022. PMID: 36375562. doi:10.1016/j.radonc.2022.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。